Ten post jest także dostępny w języku: polski
Jarek Oleszczuk was appointed to the board of the Polish start-up Genomtec. As Chief Business Officer (CBO) he will be responsible for further development and implementation of the business strategy. Will Oleszczuk’s experience gained in managing large pharmaceutical corporations help Genomtec to grow faster?
AstraZeneca, AbbVie, Abbott, Novartis…
Jarek Oleszczuk has many years of experience in working for pharmaceutical companies. Until the end of March 2020, Jarek Oleszczuk was the President of the Management Board of AstraZeneca Pharma Poland. We have written more about the activities undertaken there for nearly four years of his career here. Previously, Oleszczuk worked for, among others, Novartis, where he was Head of Commercial Operations and Director of Innovative Medicines Division in Poland, and also managed the company’s branch in the Baltic States. He was also CEO of Abbott Poland and CEO of AbbVie first in Poland and later in Belgium and Luxembourg.
Jarek Oleszczuk is not the only person who recently joined Genomtec. Earlier, the company announced the appointment of Marta Gajecka and Jakub Swadzb to the supervisory board.
Genomtec to debut on NewConnect
Genomtec became famous this year for its rapid coronavirus COVID-19 test, which detects the presence of the pathogen in just a few minutes. The company is constantly investing in the development of this solution and plans to commercialise the mobile molecular analyser in the first half of 2022. In the years 2020-2022, it will implement a project entitled “Development of mobile diagnostic equipment for the detection of COVID-19”, for which it obtained funding from the National Centre for Research and Development (NCBiR) in the amount of PLN 7m. The total cost of the project was estimated at nearly PLN 11m.
Genomtec also informed at the beginning of September that it intends to debut on NewConnect by the end of the year. Ultimately, the company would like to be listed on the WSE main market.
Photo: Jarek Oleszczuk Twitter.